News - Starpharma

Latest News

VIRALEZE™ relaunched by LloydsPharmacy in the UK (ASX Announcement)

Jun 30th, 2022

Starpharma today announced that VIRALEZE™ nasal spray has been relaunched by LloydsPharmacy in the UK.

Shareholder Newsletter June 2022

Jun 3rd, 2022

The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Newsletter June 2022 is now available to view online.

SPL7013 in VIRALEZE™ virucidal against influenza A and B (ASX Announcement)

May 18th, 2022

Starpharma today announced that SPL7013, the antiviral agent in VIRALEZE™ nasal spray, achieved 95% and 99.7% reduction in viral infectivity against two significant types of influenza virus, A and B, respectively, in virucidal assays. The virucidal assays conducted at the Scripps Research Institute in the US assessed the irreversible nature of the effect of a compound against viruses.

Quarterly Cashflow and Activities Report (ASX Announcement)

Apr 29th, 2022

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2022.

In the media

Australian biotech back on the international stage

Jun 7th, 2022

Starpharma's CEO Dr Jackie Fairley was interviewed by ausbiz during Starpharma's visit to the United States for the American Society of Clinical Oncology (ASCO) Annual Meeting as well as partnering discussions.

Starpharma one of a number of Australian companies in the US for major oncology conference

Jun 7th, 2022

"For the first time in more than two years, a number of Australian biotechnology companies are in the US for one of the world's most important oncology events - the global conference of the American Society of Clinical Oncology (ASCO)." Starpharma featured in Biotech Dispatch during its visit to the United States for ASCO.

Starpharma's nasal spray effective against influenza A & B virus

May 23rd, 2022

BioSpectrum Asia features Viraleze, following Starpharma's announcement about SPL7013's virucidal activity in influenza A and B.

Starpharma’s (ASX:SPL) antiviral agent fights back against against influenza virus

May 18th, 2022

The Market Herald reports on Starpharma’s SPL7013 agent, which achieved up to 99.7 per cent reduction in viral activity against two types of influenzas virus.

Sign up to receive news here